Colinz Laboratories Limited (BOM:531210)

India · Delayed Price · Currency is INR

82.94

+0.37 (0.45%)

At close: Jul 28, 2026

72.32% (1Y)

Market Cap	208.93M +72.3%
Revenue (ttm)	61.36M -6.0%
Net Income	5.15M +3.6%
EPS	2.04 +3.6%
Shares Out	2.52M
PE Ratio	40.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,532
Open	83.50
Previous Close	82.57
Day's Range	78.55 - 85.79
52-Week Range	36.11 - 87.91
Beta	-0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,... [Read more]

Industry Pharmaceutical Preparations

Founded 1986

Employees 65

Stock Exchange Bombay Stock Exchange

Ticker Symbol 531210

Full Company Profile

Financial Performance

In fiscal year 2026, Colinz Laboratories's revenue was 61.36 million, a decrease of -6.00% compared to the previous year's 65.28 million. Earnings were 5.15 million, an increase of 3.60%.

Financial Statements